RECORD // Company

Palvella Therapeutics, Inc.

Formerly: PIERIS PHARMACEUTICALS, INC.; Marika Inc.

Built 2026-11-22T05:12:29Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Records under a former name (4)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (5)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Palvella Therapeutics, Inc. · Ctgov · same registered legal name as 'PALVELLA THERAPEUTICS, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • PALVELLA THERAPEUTICS, INC. · East licences · same registered legal name as 'PALVELLA THERAPEUTICS, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • PALVELLA THERAPEUTICS, INC. · East licences · same registered legal name as 'PALVELLA THERAPEUTICS, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • PALVELLA THERAPEUTICS, INC. · East licences · same registered legal name as 'PALVELLA THERAPEUTICS, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • PALVELLA THERAPEUTICS, INC. · USAspending · same registered legal name as 'PALVELLA THERAPEUTICS, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001193125-26-448638

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-24,643,0003 months ended 2026-09-3010-Q2026-11-050001193125-26-4486382026-11-22 05:12 UTCReport an error
Cash and cash equivalents$193,297,000at 2026-09-3010-Q2026-11-050001193125-26-4486382026-11-22 05:12 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001583648
Ticker
PVLA
EIN
300784346
CUSIP
697947109
Record ID
sx:sec:0001583648

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

34 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-19SEC EDGAR company profile2026-11-22 05:12 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-19SEC EDGAR company profile2026-11-22 05:12 UTCReport an error
State of incorporationNV2026-11-19SEC EDGAR company profile2026-11-22 05:12 UTCReport an error
Fiscal year end (MMDD)12312026-11-19SEC EDGAR company profile2026-11-22 05:12 UTCReport an error
Business address353 W. LANCASTER AVENUE, SUITE 200, WAYNE, PA, 190872026-11-19SEC EDGAR company profile2026-11-22 05:12 UTCReport an error
ExchangesNasdaq2026-11-19SEC EDGAR company profile2026-11-22 05:12 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-41,715,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 05:12 UTCReport an error
Total assets (at 2025-12-31)$59,559,0002025-12-3110-K, XBRL Assets2026-11-22 05:12 UTCReport an error
Stockholders' equity (at 2025-12-31)$27,983,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 05:12 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$57,982,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 05:12 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-25,006,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 05:12 UTCReport an error
Operating lease liabilities (at 2025-12-31)$633,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 05:12 UTCReport an error
Form D total offering amount (D filed 2019-11-20)$32,003,1082019-11-20D2026-11-22 05:12 UTCReport an error
Form D total amount sold (D filed 2019-11-20)$32,003,1082019-11-20D2026-11-22 05:12 UTCReport an error
Form D industry groupPharmaceuticals2019-11-20D2026-11-22 05:12 UTCReport an error
Form D revenue rangeDecline to Disclose2019-11-20D2026-11-22 05:12 UTCReport an error
Form D date of first sale2019-11-062019-11-20D2026-11-22 05:12 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-19)On November 19, 2026, Palvella Therapeutics, Inc. (the “Company”) will host a conference call with investors at 8:30 a.m. Eastern Time, to present a new QTORIN™ program, the third product candidate from the Company's QTORIN™ platform. The live event and accompanying slides can be accessed by visiting https://edge.media-server.com/mmc/p/5m7e3b3n/. A copy of the investor presentation is furnished herewith as Exhibit 99.1, and incorporated herein by reference. The information furnished pursuant to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)…2026-11-19SEC EDGAR 8-K 0001193125-26-467823 (text as filed, excerpt)2026-11-22 05:12 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-19)On November 19, 2026, the Company also issued a press release announcing the third product candidate from the Company's QTORIN™ program, for the treatment of Extramammary Paget’s disease. A copy of the press release is filed herewith as Exhibit 99.2, and incorporated herein by reference.2026-11-19SEC EDGAR 8-K 0001193125-26-467823 (text as filed, excerpt)2026-11-22 05:12 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-05)On November 5, 2026, Palvella Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended…2026-11-05SEC EDGAR 8-K 0001193125-26-448594 (text as filed, excerpt)2026-11-22 05:12 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-05)On November 5, 2026, the Company will hold its earnings call and use a slide presentation in conjunction with the earnings call. A copy of the presentation is furnished herewith as Exhibit 99.2, and incorporated herein by reference. The information furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.2026-11-05SEC EDGAR 8-K 0001193125-26-448594 (text as filed, excerpt)2026-11-22 05:12 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-28)On October 28, 2026, Palvella Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has accepted for filing and granted Priority Review to the Company’s New Drug Application for QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations. The FDA has assigned a Prescription Drug User Fee Act target action date of February 28, 2027. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.2026-10-28SEC EDGAR 8-K 0001193125-26-435113 (text as filed, excerpt)2026-11-22 05:12 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-04)On August 4, 2026, Palvella Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the…2026-08-04SEC EDGAR 8-K 0001193125-26-331556 (text as filed, excerpt)2026-11-22 05:12 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-04)On August 4, 2026, the Company will hold its earnings call and use a slide presentation in conjunction with the earnings call. A copy of the presentation is furnished herewith as Exhibit 99.2, and incorporated herein by reference. The information furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.2026-08-04SEC EDGAR 8-K 0001193125-26-331556 (text as filed, excerpt)2026-11-22 05:12 UTCReport an error
Largest institutional holder #1 (13F as filed): MONTANOVA CAPITAL, LLC$173,512,7452026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #2 (13F as filed): JENNISON ASSOCIATES LLC$146,801,7952026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #3 (13F as filed): BlackRock, Inc.$140,343,3172026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #4 (13F as filed): Frazier Life Sciences Management, L.P.$134,848,3682026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #5 (13F as filed): First Light Asset Management, LLC$117,961,9112026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #6 (13F as filed): BVF INC/IL$102,815,6152026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #7 (13F as filed): STATE STREET CORP$99,817,7452026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #8 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$78,517,9992026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #9 (13F as filed): FRONTIER CAPITAL MANAGEMENT CO LLC$73,175,2722026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #10 (13F as filed): FEDERATED HERMES, INC.$66,173,3522026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.